Tomaralimab  (Synonyms: 托拉利单抗; OPN-305)

Tomaralimab (OPN-305) is a humanized anti-TLR2 IgG4 monoclonal antibody. Tomaralimab inhibits TLR2, MyD88, NLRP3, and reduces pro-inflammatory cytokine (IL-1β, IL-6, IL-8) production. Tomaralimab reduces tau pathology. Tomaralimab improves cognition, atopic dermatitis. Tomaralimab has anticancer effects on pancreatic ductal adenocarcinoma. Tomaralimab is being studied in myelodysplastic syndrome (MDS), atopic dermatitis, pancreatic ductal adenocarcinoma, Alzheimer's disease, and myocardial ischemia/reperfusion injury^{[1][2][3][4][5]}.

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Chimeric

Tomaralimab (100-500 nM；20 h) 在 HEK-Blue hTLR2 细胞中以剂量依赖性方式抑制寡聚 tau 诱导的 TLR2 活化，降低 SEAP 水平^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Tomaralimab (30 mg/kg；静脉注射；每周一次；8-15 周) 可降低 rTg4510 tau 转基因小鼠的 tau 病理和小胶质细胞活化，改善认知能力^[1]。
Tomaralimab (25 mg/kg；静脉注射；隔日一次；直至第 19 天) 可减轻 BALB/c 小鼠中 DNCB 诱发的特应性皮炎 (AD) 样皮肤病变^[2]。
Tomaralimab (10 mg/kg；腹腔注射；每周两次) 可抑制移植人胰腺导管腺癌 (PDAC) 异种移植瘤的 NSG 小鼠的肿瘤生长并减少 PCNA 阳性增殖细胞^[3]。
Tomaralimab (1.56-12.5 mg/kg；静脉注射；再灌注前 15 min) 在猪心肌缺血/再灌注模型中，剂量依赖性地减少梗塞面积高达 45%，并保留心脏功能^[5]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.32 kDa

1449294-76-1

液体

Colorless to light yellow

托拉利单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• 
  Immobilized Human TLR2 Protein can bind Tomaralimab. The EC₅₀ for this effect is 649.63 ng/mL.

• [1]. Kim Y, et al. TLR2 immunotherapy suppresses neuroinflammation, tau spread, and memory loss in rTg4510 mice. Brain Behav Immun. 2024 Oct;121:291-302.  [Content Brief]

  [2]. Yeo H, et al. Therapeutic potential of a systemically applied humanized monoclonal antibody targeting Toll‑like receptor 2 in atopic‑dermatitis‑like skin lesions in a mouse model. Biomed Rep. 2024 Dec 30;22(3):41.  [Content Brief]

  [3]. Lundy J, et al. TLR2 activation promotes tumour growth and associates with patient survival and chemotherapy response in pancreatic ductal adenocarcinoma. Oncogene. 2021 Oct;40(41):6007-6022.  [Content Brief]

  [4]. GuillermoGarcia-ManeroMD, et al. A Clinical Study of Tomaralimab (OPN-305), a Toll-like Receptor 2 (TLR-2) Antibody, in Heavily Pre-Treated Transfusion Dependent Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received and Failed on Prior Hypomethylating Agent (HMA) Therapy. Blood, 2018, 798.

  [5]. Arslan F, et al. Treatment with OPN-305, a humanized anti-Toll-Like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs. Circ Cardiovasc Interv. 2012 Apr;5(2):279-87.  [Content Brief]